Aflibercept, Bevacizumab, or Ranibizumab for XXXX .

@entity1 @entity227 @entity204 @entity1103
UNASSIGNED: Background The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of @entity1103 are unknown. Methods At 89 clinical sites, we randomly assigned 660 adults (mean age, 61  10 years) with @entity1103 involving the macular center to receive intravitreous aflibercept at a dose of 2.0 mg (224 @entity1 ), bevacizumab at a dose of 1.25 mg (218 @entity1 ), or ranibizumab at a dose of 0.3 mg (218 @entity1 ). The study drugs were administered as often as every 4 weeks, according to a protocol-specified algorithm. The primary outcome was the mean change in visual acuity at 1 year. Results From baseline to 1 year, the mean @entity227 letter score (range, 0 to 100, with higher scores indicating better visual acuity; a score of 85 is approximately 20/20) improved by 13.3 with aflibercept, by 9.7 with bevacizumab, and by 11.2 with ranibizumab. Although the improvement was greater with aflibercept than with the other two drugs (P<0.001 for aflibercept vs. bevacizumab and P=0.03 for aflibercept vs. ranibizumab), it was not clinically meaningful, because the difference was driven by the eyes with worse visual acuity at baseline (P<0.001 for interaction). When the initial @entity227 letter score was 78 to 69 (equivalent to approximately 20/32 to 20/40) (51% of @entity1 ), the mean improvement was 8.0 with aflibercept, 7.5 with bevacizumab, and 8.3 with ranibizumab (P>0.50 for each pairwise comparison). When the initial letter score was less than 69 (approximately 20/50 or worse), the mean improvement was 18.9 with aflibercept, 11.8 with bevacizumab, and 14.2 with ranibizumab (P<0.001 for aflibercept vs. bevacizumab, P=0.003 for aflibercept vs. ranibizumab, and P=0.21 for ranibizumab vs. bevacizumab). There were no significant differences among the study groups in the rates of serious adverse events (P=0.40), hospitalization (P=0.51), @entity204 (P=0.72), or major cardiovascular events (P=0.56). Conclusions Intravitreous aflibercept, bevacizumab, or ranibizumab improved vision in eyes with center-involved @entity1103 , but the relative effect depended on baseline visual acuity. When the initial @entity227 was mild, there were no apparent differences, on average, among study groups. At worse levels of initial visual acuity, aflibercept was more effective at improving vision. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01627249 .).
